

Welcome to STN International! Enter x:x

LOGINID:sssptal600dxk

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and
IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and
ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 CA Section Thesaurus available in CAPLUS and CA
NEWS 26 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 27 Oct 21 EVENTLINE has been reloaded
NEWS 28 Oct 24 BEILSTEIN adds new search fields
NEWS 29 Oct 24 Nutraceuticals International (NUTRACEUT) now available on
STN
NEWS 30 Oct 25 MEDLINE SDI run of October 8, 2002
NEWS 31 Nov 18 DKILIT has been renamed APOLLIT
NEWS 32 Nov 25 More calculated properties added to REGISTRY
NEWS 33 Dec 02 TIBKAT will be removed from STN
NEWS 34 Dec 04 CSA files on STN
NEWS 35 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 36 Dec 17 TOXCENTER enhanced with additional content
NEWS 37 Dec 17 Adis Clinical Trials Insight now available on STN
NEWS 38 Dec 30 ISMEC no longer available
NEWS 39 Jan 13 Indexing added to some pre-1967 records in CA/CAPLUS

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,
CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),

AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:17:12 ON 20 JAN 2003

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:17:19 ON 20 JAN 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 JAN 2003 HIGHEST RN 479481-27-1

DICTIONARY FILE UPDATES: 19 JAN 2003 HIGHEST RN 479481-27-1

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> e paclitaxel/cn

E1	1	PACKY N 50/CN
E2	1	PACKZOL/CN
E3	1 -->	PACLITAXEL/CN
E4	1	PACLITAXEL 2'-(ALL-CIS-4,7,10,13,16,19-DOCOSAHEXAENOATE)/CN
E5	1	PACLITAXEL 6.ALPHA.-HYDROXYLASE/CN
E6	1	PACLITAXEL 6.ALPHA.-MONOOXYGENASE/CN
E7	1	PACLITAXEL 7-(ALL-CIS-4,7,10,13,16,19-DOCOSAHEXAENOATE)/CN
E8	1	PACLITAXEL C/CN

E9 1 PACLITAXEL DIHYDRATE/CN
E10 1 PACLITAXEL SUCCINATE/CN
E11 1 PACLITAXEL-2'-ACETATE/CN
E12 1 PACLITAXEL-3'-14C/CN

=> s e3

L1 1 PACLITAXEL/CN

=> d l1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS

RN 33069-62-4 REGISTRY

CN Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-hydroxy-,

(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-
2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-
tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl
ester, (.alpha.R,.beta.S)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid
deriv.

CN Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-hydroxy-,
6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-
dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-
cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-

[2a.alpha.,4.beta.,4a.beta.,6.beta.,9.alpha.(.alpha.R*,.beta.S*),11.alpha.
,12.alpha.,12a.alpha.,12b.alpha.]]-

CN Tax-11-en-9-one,

5.beta.,20-epoxy-1,2.alpha.,4,7.beta.,10.beta.,13.alpha.-
hexahydroxy-, 4,10-diacetate 2-benzoate 13-ester with
(2R,3S)-N-benzoyl-3-
phenylisoserine (8CI)

OTHER NAMES:

CN ABI 007

CN BMS 181339-01

CN NSC 125973

CN **Paclitaxel**

CN Plaxicel

CN Taxol

CN Taxol A

CN Yewtaxan

FS STEREOSEARCH

MF C47 H51 N O14


CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB,
CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSChem, DDFU, DETHERM*,
DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, HSDB*, IFICDB,
IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, PHAR, PHARMASEARCH,
PIRA, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL,

VETU

(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (-).



6727 REFERENCES IN FILE CA (1962 TO DATE)
 365 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 6752 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> d rn cn

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS

RN 33069-62-4 REGISTRY

CN Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-hydroxy-,

(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (.alpha.R,.beta.S)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.

CN Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-

[2a.alpha.,4.beta.,4a.beta.,6.beta.,9.alpha.(.alpha.R*,.beta.S*),11.alpha.,12.alpha.,12a.alpha.,12b.alpha.]]-

CN Tax-11-en-9-one,

5.beta.,20-epoxy-1,2.alpha.,4,7.beta.,10.beta.,13.alpha.-hexahydroxy-, 4,10-diacetate 2-benzoate 13-ester with

(2R,3S)-N-benzoyl-3-phenylisoserine (8CI)

OTHER NAMES:

CN ABI 007

CN BMS-181339-01

CN NSC 125973

CN **Paclitaxel**

CN Plaxicel

CN Taxol

CN Taxol A

CN Yewtaxan

=> e docetaxel/cn

E1 1 DOCENTAL/CN

E2 1 DOCETAXAL/CN

E3 1 --> DOCETAXEL/CN
 E4 1 DOCETAXEL HEMIHYDRATE/CN
 E5 1 DOCETAXEL TRIHYDRATE/CN
 E6 1 DOCEVITA/CN
 E7 1 DOCEYLPENTADECYL ACRYLATE-METHYL ACRYLATE-1-OCTADECENE
 POLYM
 ER/CN
 E8 1 DOCHC/CN
 E9 1 DOCHLOXYTHEPIN/CN
 E10 1 DOCI/CN
 E11 1 DOCIBIN/CN
 E12 1 DOCIGRAM/CN

=> s e3

L2 1 DOCETAXEL/CN

=> d 12

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
 RN 114977-28-5 REGISTRY
 CN Benzenepropanoic acid, .beta.-[[(1,1-dimethylethoxy) carbonyl] amino] -
 .alpha.-hydroxy-,
 (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-
 (benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-
 trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-
 cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (.alpha.R,.beta.S)- (9CI) (CA
 INDEX NAME)

OTHER CA INDEX NAMES:

CN 7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid
 deriv.

CN Benzenepropanoic acid, .beta.-[[(1,1-dimethylethoxy) carbonyl] amino] -
 .alpha.-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-

2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-
 tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl
 ester,

[2aR-[2a.alpha.,4.beta.,4a.beta.,6.beta.,9.alpha. (.alpha.R*,.beta.S
 *),11.alpha.,12.alpha.,12a.alpha.,12b.alpha.]]-

OTHER NAMES:

CN Docetaxel

CN RP 56976

CN Taxotere

FS STEREOSEARCH

DR 216252-50-5


MF C43 H53 N O14

CI COM

SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
 BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB,
 CEN, CHEMCATS, CHEMINFORMRX, CIN, CSCHM, DDFU, DIOGENES, DRUGNL,
 DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, HSDB*, IPA, MEDLINE, MRCK*,
 MSDS-OHS, PHAR, PHARMASEARCH, PIRA, PROMT, RTECS*, SYNTHLINE,
 TOXCENTER,
 USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)

Absolute stereochemistry.



1367 REFERENCES IN FILE CA (1962 TO DATE)
 63 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1377 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

15.48

15.69

STN INTERNATIONAL LOGOFF AT 12:20:36 ON 20 JAN 2003

Welcome to STN International! Enter x:x

LOGINID:sssptal600dxk

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and
IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and
ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 CA Section Thesaurus available in CAPLUS and CA
NEWS 26 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 27 Oct 21 EVENTLINE has been reloaded
NEWS 28 Oct 24 BEILSTEIN adds new search fields
NEWS 29 Oct 24 Nutraceuticals International (NUTRACEUT) now available on
STN
NEWS 30 Oct 25 MEDLINE SDI run of October 8, 2002
NEWS 31 Nov 18 DKILIT has been renamed APOLLIT
NEWS 32 Nov 25 More calculated properties added to REGISTRY
NEWS 33 Dec 02 TIBKAT will be removed from STN
NEWS 34 Dec 04 CSA files on STN
NEWS 35 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 36 Dec 17 TOXCENTER enhanced with additional content
NEWS 37 Dec 17 Adis Clinical Trials Insight now available on STN
NEWS 38 Dec 30 ISMEC no longer available
NEWS 39 Jan 13 Indexing added to some pre-1967 records in CA/CAPLUS

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,
CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:05:32 ON 20 JAN 2003

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:05:43 ON 20 JAN 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 JAN 2003 HIGHEST RN 479481-27-1

DICTIONARY FILE UPDATES: 19 JAN 2003 HIGHEST RN 479481-27-1

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STN Note 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> e 4-desacetyl-4-methylcarbonate taxol/cn

E1	1	4-DEOXYWILFORINE/CN
E2	1	4-DESACETOXYVINDOLINE/CN
E3	0 -->	4-DESACETYL-4-METHYLCARBONATE TAXOL/CN
E4	1	4-DESACETYLVINBLASTINE/CN
E5	1	4-DESACETYLVINBLASTINE 3-CARBOHYDRAZIDE/CN
E6	1	4-DESACETYLVINBLASTINE 3-CARBOXYHYDRAZIDE/CN
E7	1	4-DESACETYLVINBLASTINE N-OXIDE/CN
E8	1	4-DESACETYLVINBLASTINE N-OXIDE/CN
E9	1	4-DESACETYLVINBLASTINE N-OXIDE/CN
E10	1	4-DESACETYLVINBLASTINE N-OXIDE/CN

E11 1 4-DESACETYLVINCALEUKOBLASTINE
3-(2-CHLOROETHYL) CARBOXAMIDE/C
N
E12 1 4-DESACETYLVINCALEUKOBLASTINE 3-(2-CHLOROETHYL) CARBOXAMIDE
S
ULFATE/CN

=> s e5

L1 1 "4-DESACETYLPACLITAXEL 4-METHYL CARBONATE"/CN

=> d rn cn

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
RN 172481-83-3 REGISTRY
CN Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-hydroxy-,
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6-(acetyloxy)-12-(benzoyloxy)-
2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-12b-
[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-
cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (.alpha.R,.beta.S)- (9CI) (CA
INDEX NAME)

OTHER CA INDEX NAMES:

CN Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-hydroxy-,
6-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-
4,11-dihydroxy-12b-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-
7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester,

[2aR-[2a.alpha.,4.beta.,4a.beta.,6.beta.,9.alpha.(.alpha.R*,.beta.S*),11.a
lpha.,12.alpha.,12a.alpha.,12b.alpha.]]-

OTHER NAMES:

CN 4-Desacetylpaclitaxel 4-methyl carbonate

=> d l1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
RN 172481-83-3 REGISTRY
CN Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-hydroxy-,
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6-(acetyloxy)-12-(benzoyloxy)-
2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-12b-
[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-
cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (.alpha.R,.beta.S)- (9CI) (CA
INDEX NAME)

OTHER CA INDEX NAMES:

CN Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-hydroxy-,
6-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-
4,11-dihydroxy-12b-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-
7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester,

[2aR-[2a.alpha.,4.beta.,4a.beta.,6.beta.,9.alpha.(.alpha.R*,.beta.S*),11.a
lpha.,12.alpha.,12a.alpha.,12b.alpha.]]-

OTHER NAMES:

CN 4-Desacetylpaclitaxel 4-methyl carbonate


FS STEREOSEARCH

MF C47 H51 N O15

SR CA

LC STN Files: CA, CAPLUS, CASREACT, SYNTHLINE, TOXCENTER, USPAT2,
USPATFULL

Absolute stereochemistry.



9 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 9 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> fil .carb
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
10.78	10.99

FILE 'MEDLINE' ENTERED AT 12:10:29 ON 20 JAN 2003

FILE 'BIOSIS' ENTERED AT 12:10:29 ON 20 JAN 2003
 COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'BIOTECHDS' ENTERED AT 12:10:29 ON 20 JAN 2003
 COPYRIGHT (C) 2003 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION



FILE 'CAPLUS' ENTERED AT 12:10:29 ON 20 JAN 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l1
 L2 9 L1

=> d l9 abs ibib 1-9
 L9 NOT FOUND
 The L-number entered has not been defined in this session, or it has been deleted. To see the L-numbers currently defined in this session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> d l2 abs ibib 1-9

L2 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2003 ACS
 GI



AB The present invention provides a synergistic method for the treatment of cancer which comprises administering a synergistically, therapeutically effective amt. of: (i) at least agent selected from the group consisting of cytotoxic agents and cytostatic agents, and (ii) a compd. of formula [I; R1 = Cl, Br, CN, substituted Ph, substituted pyridyl; R2 = alkyl, aralkyl; R3, R5 = substituted alkyl, aryl, heterocycle; R4 = H, alkyl; Z1

= CO, SO2, CO2, SO2N(R5); n = 1,2] or a pharmaceutically acceptable salt thereof. The present invention further provides a pharmaceutical compn. for the synergistic treatment of cancer which comprises at least one agent

selected from the group consisting of antiproliferative cytotoxic agents and antiproliferative cytostatic agents, a compd. of formula I, and a pharmaceutically acceptable carrier. Synergism was obsd. when non-proliferating tumor cells were treated with diazepam II.cntdot.HCl and paclitaxel (III) simultaneously or when III preceded II.cntdot.HCl.

ACCESSION NUMBER: 2001:730715 CAPLUS
DOCUMENT NUMBER: 135:288636
TITLE: Synergistic methods and compositions for treating cancer using two or more anticancer agents
INVENTOR(S): Lee, Francis Y.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001072721	A2	20011004	WO 2001-US9193	20010322
WO 2001072721	A3	20020613		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1272193	A2	20030108	EP 2001-920653	20010322
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			

US 2002002162 A1 20020103 US 2001-817456 20010326
PRIORITY APPLN. INFO.: US 2000-192278P P 20000327
WO 2001-US9193 W 20010322
OTHER SOURCE(S): MARPAT 135:288636

L2 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2003 ACS

AB A method for inhibiting hair loss and/or promoting hair growth in chemotherapy and/or radiation therapy patients wherein the (R)-enantiomer of

4-[[[(cyanoimino)-[(1,2,2-trimethylpropyl)amino]methyl]amino]benzonitrile is administered prior to, simultaneous with and/or after chemotherapy and/or radiation treatment. There was a remarkable difference between the

1-(R)-enantiomer and the 2-(S)enantiomer in their effect on hair follicle stimulation; in particular the (R)-enantiomer had a faster onset of action

compared to the corresponding (S)-enantiomer. While the IC50 for vasorelaxant potency of the (R)-enantiomer is 47.+-.17 nM vs. 157.+-.35 nM

for the (S)-enantiomer, the hair growth promoting ability of the (R)-enantiomer for producing hair growth within 11 days of treatment is 8 times greater than the corresponding (S)-enantiomer.

ACCESSION NUMBER: 2001:658077 CAPLUS

DOCUMENT NUMBER: 135:205580

TITLE: Method for inhibiting or treating chemotherapy-induced hair loss

INVENTOR(S): Atwal, Karnail S.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 8 pp., Cont.-in-part of U.S. Ser. No. 447,002.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001020038	A1	20010906	US 2001-805347	20010313
US 6458835	B2	20021001		
US 6013668	A	20000111	US 1998-119884	19980721
ZA 9807220	A	20000214	ZA 1998-7220	19980812
US 6472427	B1	20021029	US 1999-447002	19991122
US 6262122	B1	20010717	US 2000-615345	20000712
PRIORITY APPLN. INFO.:			US 1997-55568P	P 19970813
			US 1998-71364P	P 19980115
			US 1998-119884	A1 19980721
			US 1999-447002	A2 19991122

L2 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2003 ACS

AB A process for the synthesis of C-4 Me carbonate paclitaxel analog from 10-deacetylbaccatin III is described by the selective redn. of the acetate

at the C-4 position of 10-deacetylbaccatin III using Red-Al.

ACCESSION NUMBER: 2001:115139 CAPLUS

DOCUMENT NUMBER: 134:163187

TITLE: Process for the preparation of a paclitaxel C-4 methyl carbonate analog



INVENTOR(S): Kant, Joydeep

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 22 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001010856	A1	20010215	WO 2000-US21260	20000803
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1206461	A1	20020522	EP 2000-952478	20000803
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
US 6248908	B1	20010619	US 2000-635553	20000810
US 2001044549	A1	20011122	US 2001-813085	20010320
US 6353120	B2	20020305		
PRIORITY APPLN. INFO.:			US 1999-148392P	P 19990811
			WO 2000-US21260	W 20000803
			US 2000-635553	A3 20000810
OTHER SOURCE(S):			CASREACT 134:163187	
REFERENCE COUNT: 1			THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS	
			RECORD. ALL CITATIONS AVAILABLE IN THE RE	

FORMAT

L2 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2003 ACS
 GI



AB Novel reaction conditions for the cleavage of silyl ethers from silyl protected taxane precursors I {R1 = Me, Ph, 4-Me-, 4-NO2-C6H4, cyclohexyl; R2 = Me, Et, n-Pr, CMe3, Bu, pentyl, Ph, 4-NO2-C6H4, cyclopropyl, cyclobutyl, OMe; R3 = Si[(CHMe2)2]2OMe, SiEt3, SiMe3, SiMe2CMe3; R4 = H, Me, Ph, acetyl, benzoyl, pentanoyl; R5 = (4S,5R)-4,5-dihydro-2,4-diphenyl-5-oxazolecarbonyl, (2R,3S)-R7CH(NHCOR8)CHR6CO-; R6 = H, F, OH, OMe, OSiEt3, OSiMe2CMe3, OCM2OMe; R7 = Ph, CMe3, CHMe2; R8 = Ph, CMe3, OCM2OMe, CH3CM3; cyclobutyl, cyclohexyloxy, 2-furyl} to afford the anti-cancer agents paclitaxel and paclitaxel analogs in high yield and quality was described. Paclitaxel was prepd. from a taxane precursor by treating the taxane precursor with a strong acid, such as trifluoroacetic acid, in a solvent such as aq. acetic acid, such that the amt. and no. of side reactions and taxane impurities are significantly minimized. Also described were the crystn. methods for the isolation of paclitaxel in either of the two crystal forms A or B. Thus, taxane silyl ether II was reacted with trifluoroacetic acid and glacial acetic acid in water for

5-7

h., followed by treatment of the unisolated intermediate with sulfuric acid in water to give paclitaxel in 86.9% yield.

ACCESSION NUMBER: 2000:824239 CAPLUS
DOCUMENT NUMBER: 133:362862
TITLE: Novel reaction conditions for the cleavage of silyl ethers in the preparation of paclitaxel (Taxol) and paclitaxel analogues
INVENTOR(S): Singh, Ambarish; Weaver, Raymond E., Jr.; Powers, Gerald L.; Rosso, Victor W.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000069840	A1	20001123	WO 2000-US12469	20000508
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1178979	A1	20020213	EP 2000-932151	20000508
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002544269	T2	20021224	JP 2000-618257	20000508
US 6184395	B1	20010206	US 2000-571234	20000516
PRIORITY APPLN. INFO.:			US 1999-134469P	P 19990517
			WO 2000-US12469	W 20000508
OTHER SOURCE(S):		CASREACT 133:362862; MARPAT 133:362862		
REFERENCE COUNT:		1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE		

FORMAT

L2 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2003 ACS

AB A series of 98 paclitaxel analogs were investigated using the comparative mol. field anal. (CoMFA) and a high predictive 3D-QSAR model with a significant cross-validated .gamma.cv2, conventional .gamma.2, and predictive .gamma.pred.2 equaling to 0.714, 0.901, 0.812, resp., was obtained. It revealed that the changes of the C-13 side chain groups, esp. 2'-OH, affected the activity significantly and others did less relatively. It also showed that the model was significant for the research and development of novel paclitaxel analogs to reduce the blind flight during drug designing.

ACCESSION NUMBER: 2000:218668 CAPLUS
 DOCUMENT NUMBER: 133:255
 TITLE: Studies on the quantitative structure-activity relationships of paclitaxel analogs
 AUTHOR(S): Shi, Bing-Xing; Liang, Shi-Le; Yuan, Ying-Jin; Sun, Ming; Miao, Fang-Ming
 CORPORATE SOURCE: Department of Biochemical Engineering, Tianjin University, Tianjin, 300072, Peop. Rep. China
 SOURCE: Gaodeng Xuexiao Huaxue Xuebao (2000), 21(3), 401-406
 CODEN: KTHPDM; ISSN: 0251-0790
 PUBLISHER: Gaodeng Jiaoyu Chubanshe
 DOCUMENT TYPE: Journal
 LANGUAGE: Chinese

L2 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2003 ACS

AB The semisynthesis and biol. activity of paclitaxel (Taxol) analogs in which the oxygen atom in ring D is substituted by a sulfur or a selenium atom is presented. These derivs. were synthesized and tested in order to make more transparent the role of the oxetane ring in the biol. activity of paclitaxel. The sulfur derivs. were found to be less active than paclitaxel in biol. assays, while the selenium deriv. could not be converted to its 4-acyl analog. The results with the sulfur analogs suggest that the oxygen atom in the oxetane ring plays an important role in the mechanism by which paclitaxel exhibits its anticancer activity.

ACCESSION NUMBER: 1999:202337 CAPLUS
 DOCUMENT NUMBER: 131:5390
 TITLE: Synthesis and Biological Evaluation of Novel

Paclitaxel (Taxol) D-Ring Modified Analogs
AUTHOR(S): Gunatilaka, A. A. Leslie; Ramdayal, Frank D.;
Sarragiotto, Maria H.; Kingston, David G. I.;
Sackett,
Dan L.; Hamel, Ernest
CORPORATE SOURCE: Department of Chemistry, Virginia Polytechnic
Institute and State University, Blacksburg, VA,
24061-0212, USA
SOURCE: Journal of Organic Chemistry (1999), 64(8), 2694-2703
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR
THIS


RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L2 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2003 ACS
AB A series of 94 paclitaxel analogs exhibiting antitumor activity by
promoting the assembly of microtubules and inhibiting the disassembly
process of microtubules to tubulin were investigated using the
comparative
mol. field anal. (CoMFA) method. These compds. belonging to 10
structural
classes were randomly divided into a training set of 80 compds. and a
test
set of 14 compds. Since the 3-dimensional structure of ligand-receptor
complex is unknown, from x-ray and NMR data, the authors rationally
selected the 3-dimensional structure of paclitaxel in a polar soln. as
the
active conformation and starting structure for mol. modeling, the other
mols. were aligned using this mol. model as the template. The most
optimal CoMFA yielded a 2-component model, with significant
cross-validation r^2_{cv} of 0.640 and conventional r^2 of 0.868. The
predictive ability of training set model was tested on the test set of 14
compds. The tests not only revealed the robustness of the CoMFA model
but
demonstrated that for this model r^2_{pred} based on the mean activity of
test
set compds. can accurately est. external predictivity but r^2_{pred} based on
the mean activity of training set compds. overestimated the model. The
CoMFA model explained why the activity of taxoid is sensitive to the
stereochem. of the atoms at C-2' and C-3' positions and the presence of
hydroxyl group at C-2' position. The other factors affecting activity
were also elucidated according to std. coeff. contour maps of steric and
electrostatic fields derived from the CoMFA model.

ACCESSION NUMBER: 1998:31653 CAPLUS
DOCUMENT NUMBER: 128:30043
TITLE: Comparative Molecular Field Analysis of A Series of
Paclitaxel Analogs
AUTHOR(S): Zhu, Qiqing; Guo, Zongru; Huang, Niu; Wang, Minmin;
Chu, Fengming
CORPORATE SOURCE: Department of Synthetic Medicinal Chemistry Institute of
Materia Medica Chinese Academy of Medical
Sciences,
Peking Union Medical College, Beijing, 100050, Peop.
Rep. China
SOURCE: Journal of Medicinal Chemistry (1997), 40(26),
4319-4328
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

L2 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2003 ACS
GI



AB Several C-13 amidopaclitaxel analogs have been synthesized during the course of our structure-activity relationship study at the C-13 position. These include 4-deacetyl-13-amidopaclitaxel (I; R = H, R' = Bz, R'' = Ph), 13-amidopaclitaxel 4-(Me carbonate) derivs. (I; R = CO₂Me, R' = Bz, R'' = Ph, 2-furyl), and 13-amidopaclitaxel (I; R = Ac, R' = Bz, R'' = Ph). None of these novel C-13 amidopaclitaxel analogs retain any activity in the tubulin polymn. assay or the in vitro cytotoxicity assay.

ACCESSION NUMBER: 1996:136175 CAPLUS
DOCUMENT NUMBER: 124:289921
TITLE: Synthesis and Biological Evaluation of C-13 Amide-Linked Paclitaxel (Taxol) Analogs
AUTHOR(S): Chen, Shu-Hui; Farina, Vittorio; Vyas, Dolatrai M.; Doyle, Terrence W.; Long, Byron H.; Fairchild, Craig
CORPORATE SOURCE: Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT, CONNECTICUT, USA
SOURCE: Journal of Organic Chemistry (1996), 61(6), 2065-70
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 124:289921

L2 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2003 ACS

AB A large no. of C-4 paclitaxel analogs have been prepd. in the course of our systematic C-4 modification. These include C-4 esters, carbonates, carbamates as well as a C-4 deacetyl derivs. All of these analogs were evaluated in a tubulin polymn. assay as well as in a cytotoxicity assay against a human colon cancer cell line. The potent analogs emerging from these in vitro assays were further evaluated in vivo. With the exception of paclitaxel side chain bearing C-4 carbamates and C-4 arom. esters,

most

of the C-4 aliph. esters and carbonates were found to possess comparable or superior activity to paclitaxel in vitro. Several C-4 aliph. esters and carbonates also exhibited in vivo activities against i.p. implanted murine M-109 lung carcinoma.

ACCESSION NUMBER: 1995:959365 CAPLUS
DOCUMENT NUMBER: 124:176562
TITLE: Novel C-4 paclitaxel (Taxol) analogs: potent antitumor agents
AUTHOR(S): Chen, Shu-Hui; Wei, Jian-Mei; Long, Byron H.;

W.; Fairchild, Craig A.; Carboni, Joan; Mamber, Steven
 Rose, William C.; Johnston, Kathy; Casazza, Anna M.;
 et al.
 CORPORATE SOURCE: Bristol-Myers Squibb Pharmaceutical Res. Inst.,
 Wallingford, CT, 06492-7660, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1995),
 5(22), 2741-6
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English

=> s 4-desacetyl-4-methylcarbonate(w)taxol?
 L3 1 4-DESACETYL-4-METHYLCARBONATE(W) TAXOL?

=> d l3

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:240547 CAPLUS
 DN 136:257231
 TI Method for reducing toxicity of combined chemotherapies
 IN Minotti, Giorgio; Gianni, Luca
 PA Bristol-Myers Squibb Company, USA
 SO PCT Int. Appl., 24 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002024179	A2	20020328	WO 2001-US27620	20010906
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2001088805	A5	20020402	AU 2001-88805	20010906
	US 2002049170	A1	20020425	US 2001-954953	20010918
PRAI	US 2000-234496P	P	20000922		
	WO 2001-US27620	W	20010906		

=> d l3 abs ibib

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS
 AB Compns. and methods are provided for use in the treatment of cancer. A method for the treatment of cancer is provided comprising administration of **4-desacetyl-4-methylcarbonate taxol** and doxorubicin to a patient in need thereof. Surprisingly, it has been found that 4-desacetyl 4-Me carbonate taxol does not stimulate formation of cardiotoxic metabolic doxorubicin byproducts. Also provided with the present invention is a chemotherapeutic compn. comprising a chemotherapeutically effective amt. of 4-desacetyl 4-Me carbonate taxol and doxorubicin. In a further embodiment of the invention, the

chemotherapeutic compn. is disposed within a pharmaceutically acceptable carrier. Alternatively, each agent, 4-desacetyl 4-Me carbonate taxol and doxorubicin may be formulated sep. to facilitate sequential administration of the compns.

ACCESSION NUMBER: 2002:240547 CAPLUS
DOCUMENT NUMBER: 136:257231
TITLE: Method for reducing toxicity of combined chemotherapies
INVENTOR(S): Minotti, Giorgio; Gianni, Luca
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002024179	A2	20020328	WO 2001-US27620	20010906
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001088805	A5	20020402	AU 2001-88805	20010906
US 2002049170	A1	20020425	US 2001-954953	20010918
PRIORITY APPLN. INFO.:			US 2000-234496P	P 20000922
			WO 2001-US27620	W 20010906

	SINCE FILE	TOTAL
=> log y		
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	40.95	51.94
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	-6.51	-6.51

STN INTERNATIONAL LOGOFF AT 12:16:30 ON 20 JAN 2003

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:

LOGINID:ssspta1600dxk

STN INTERNATIONAL LOGOFF AT 11:38:55 ON 30 JAN 2002

Connection closed by remote host

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:ssspta1600dxk

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Sep 17	IMSworld Pharmaceutical Company Directory name change to PHARMASEARCH
NEWS	3	Oct 09	Korean abstracts now included in Derwent World Patents Index
NEWS	4	Oct 09	Number of Derwent World Patents Index updates increased
NEWS	5	Oct 15	Calculated properties now in the REGISTRY/ZREGISTRY File
NEWS	6	Oct 22	Over 1 million reactions added to CASREACT
NEWS	7	Oct 22	DGENE GETSIM has been improved
NEWS	8	Oct 29	AAASD no longer available
NEWS	9	Nov 19	New Search Capabilities USPATFULL and USPAT2
NEWS	10	Nov 19	TOXCENTER(SM) - new toxicology file now available on STN
NEWS	11	Nov 29	COPPERLIT now available on STN
NEWS	12	Nov 29	DWPI revisions to NTIS and US Provisional Numbers
NEWS	13	Nov 30	Files VETU and VETB to have open access
NEWS	14	Dec 10	WPINDEX/WPIDS/WPIX New and Revised Manual Codes for 2002
NEWS	15	Dec 10	DGENE BLAST Homology Search
NEWS	16	Dec 17	WELDASEARCH now available on STN
NEWS	17	Dec 17	STANDARDS now available on STN
NEWS	18	Dec 17	New fields for DPCI
NEWS	19	Dec 19	CAS Roles modified
NEWS	20	Dec 19	1907-1946 data and page images added to CA and Cplus
NEWS	21	Jan 25	BLAST(R) searching in REGISTRY available in STN on the Web
NEWS	22	Jan 25	Searching with the P indicator for Preparations
NEWS	23	Jan 29	FSTA has been reloaded and moves to weekly updates
NEWS EXPRESS			August 15 CURRENT WINDOWS VERSION IS V6.0c, CURRENT MACINTOSH VERSION IS V6.0 (ENG) AND V6.0J (JP), AND CURRENT DISCOVER FILE IS DATED 07 AUGUST 2001
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:39:36 ON 30 JAN 2002

=> file caplus

COMMAND INTERRUPTED

SESSION CONTINUES IN FILE 'HOME'

If this message appears repeatedly, please notify the Help Desk.

Enter "HELP STN" for information on contacting the nearest STN Help Desk by telephone or via SEND in the STNMAIL file.

=> file biosis

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.67

0.67

FILE 'BIOSIS' ENTERED AT 11:41:00 ON 30 JAN 2002

COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE COVERS 1969 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT

FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 24 January 2002 (20020124/ED)

The BIOSIS file has been reloaded. Enter HELP RLOAD and HELP REINDEXING for details.

=> s doxorubicin?

L1 16427 DOXORUBICIN?

=> s l1 and taxanes?

617 TAXANES?

L2 64 L1 AND TAXANES?

=> s l2 and cancer(w)therapy?

383033 CANCER

38513 CANCERS

393120 CANCER

(CANCER OR CANCERS)

523663 THERAPY?

10811 CANCER(W) THERAPY?

L3 0 L2 AND CANCER(W) THERAPY?

=> s l2 and anti-cancer?

418620 ANTI

13 ANTIS

418628 ANTI

(ANTI OR ANTIS)

395961 CANCER?

4274 ANTI-CANCER?

(ANTI(W) CANCER?)

L4 1 L2 AND ANTI-CANCER?

=> d 14 abs ibib

✓ L4 ANSWER 1 OF 1 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AB The chimeric monoclonal antibody cBR96 conjugated to **doxorubicin** (cBR96-Dox) is selectively internalized by a wide variety of human carcinomas expressing an extended form of Lewis Y antigen (Ley). Endocytosis is followed by cleavage and release of free **doxorubicin** from the endocytic vesicles and subsequent cytotoxicity. Combination studies with standard **anti-cancer** agents, undertaken to further increase the potency of this targeted therapy, identified significant synergistic anti-tumor activity of cBR96-Dox and either of the **taxanes** paclitaxel or docetaxel. Treatment with cBR96-Dox 24 hr prior to paclitaxel resulted in a steady increase in the percentage of G2 tumor cells and corresponding increase

in sensitivity to **taxanes**. Cell cycle analysis indicated the cBR96-delivered **doxorubicin** was most effective against S-phase cells, yet cells exposed to even subtoxic levels progressed to and arrested in G2, at a point of high sensitivity to the anti-tubulin agent paclitaxel. The synergy obtained by staged combination of cBR96-Dox and paclitaxel in vitro was reflected in significant anti-tumor efficacy in vivo against xenograft models of human lung and breast tumors that could not be achieved by either agent alone. The staged combination elicited significant or complete regressions of established human Ley-positive tumor xenografts using significantly reduced drug levels. Taken together, these data demonstrate a mechanistic approach to the selective elimination

of Ley-positive tumors by using targeted **doxorubicin** followed by taxane treatment.

ACCESSION NUMBER: 2001:417196 BIOSIS
DOCUMENT NUMBER: PREV200100417196
TITLE: Selective tumor sensitization to **taxanes** with the mab-drug conjugate CBR96-**doxorubicin**.
AUTHOR(S): Wahl, Alan F. (1); Donaldson, Karen L.; Mixan, Bruce J.; Trail, Pamela A.; Siegall, Clay B.
CORPORATE SOURCE: (1) Seattle Genetics, Inc., 22215 26th Ave. SE, Bothell, WA, 98021: awahl@seagen.com USA
SOURCE: International Journal of Cancer, (15 August, 2001) Vol. 93,
No. 4, pp. 590-600. print.
ISSN: 0020-7136.
DOCUMENT TYPE: Article
LANGUAGE: English
SUMMARY LANGUAGE: English

=> d 12 1-30

L2 ANSWER 1 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2002:26135 BIOSIS
DN PREV200200026135
TI Dose scheduling-Herceptin(R).
AU Leyland-Jones, Brian (1)
CS (1) Department of Oncology, McGill University, 3655 Drummond Avenue, Suite
701, Montreal, PQ, H3G 1Y6: leylandj@med.mcgill.ca Canada
SO Oncology (Basel), (October, 2001) Vol. 61, No. Suppl 2, pp. 31-36.
print.
ISSN: 0030-2414.

DT Article
LA English

L2 ANSWER 2 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AN 2002:21868 BIOSIS

DN PREV200200021868

TI Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel.

AU Taghian, Alphonse G. (1); Assaad, Sherif I.; Niemierko, Andrzej; Kuter, Irene; Younger, Jerry; Schoenthaler, Robin; Roche, Maria; Powell, Simon

N.

CS (1) Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, 100 Blossom St., Cox 3, Boston, MA, 02114: ataghian@partners.org USA

SO Journal of the National Cancer Institute (Bethesda), (December 5, 2001) Vol. 93, No. 23, pp. 1806-1811. print.
ISSN: 0027-8874.

DT Article
LA English

L2 ANSWER 3 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AN 2001:545353 BIOSIS

DN PREV200100545353

TI A pitfall in the survival benefit of adjuvant chemotherapy for node- and hormone receptor-positive patients with breast cancer: The paradoxical role of Bcl-2 oncoprotein (Review.

AU Kim, Ryungsa (1); Osaki, Akihiko; Toge, Tetsuya

CS (1) Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8553: rkim@ipc.hiroshima-u.ac.jp Japan

SO International Journal of Oncology, (November, 2001) Vol. 19, No. 5, pp. 1075-1080. print.
ISSN: 1019-6439.

DT General Review
LA English
SL English

L2 ANSWER 4 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AN 2001:476692 BIOSIS

DN PREV200100476692

TI Epirubicin in combination with the **taxanes**.

AU Trudeau, Maureen (1); Pagani, Olivia

CS (1) Toronto Sunnybrook Regional Cancer Centre, 2075 Bayview Ave, Toronto, ON, M4N-5145 Canada

SO Seminars in Oncology, (August, 2001) Vol. 28, No. 4 Suppl 12, pp. 41-50. print.
ISSN: 0093-7754.

DT Article
LA English
SL English

L2 ANSWER 5 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AN 2001:476688 BIOSIS

DN PREV200100476688

TI Pharmacokinetic profiles of **doxorubicin** in combination with **taxanes**.

AU Holmes, Frankie Ann (1); Rowinsky, Eric Keith

CS (1) 909 Frostwood Dr, No. 221, Houston, TX, 77024-2305 USA

SO Seminars in Oncology, (August, 2001) Vol. 28, No. 4 Suppl 12, pp. 8-14. print.

ISSN: 0093-7754.

DT Article
LA English
SL English

L2 ANSWER 6 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2001:466214 BIOSIS
DN PREV200100466214
TI Drug interactions with the **taxanes**: Clinical implications.
AU Baker, A. F. (1); Dorr, R. T.
CS (1) Arizona Cancer Center, 1515 N Campbell Avenue, Tucson, AZ,
85724-5024:
abaker@azcc.arizona.edu USA
SO Cancer Treatment Reviews, (August, 2001) Vol. 27, No. 4, pp. 221-233.
print.
ISSN: 0305-7372.

DT General Review
LA English
SL English

L2 ANSWER 7 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2001:425850 BIOSIS
DN PREV200100425850
TI Effects of orally active **taxanes** on P-glycoprotein modulation
and colon and breast carcinoma drug resistance.
AU Vredenburg, Michael R.; Ojima, Iwao; Veith, Jean; Pera, Paula; Kee,
Kristin; Cabral, Fernando; Sharma, Amarnath; Kanter, Peter; Greco,
William
R.; Bernacki, Ralph J. (1)
CS (1) Department of Pharmacology and Therapeutics, Roswell Park Cancer
Institute, Elm and Carlton Sts., Buffalo, NY, 14263:
Ralph.Bernacki@roswellpark.org USA
SO Journal of the National Cancer Institute (Bethesda), (August 15, 2001)
Vol. 93, No. 16, pp. 1234-1245. print.
ISSN: 0027-8874.

DT Article
LA English
SL English

L2 ANSWER 8 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2001:419077 BIOSIS
DN PREV200100419077
TI Resistance to topoisomerase poisons due to loss of DNA mismatch repair.
AU Fedier, Andre; Schwarz, Viola A.; Walt, Heinrich; Carpin, Renato Delli;
Haller, Urs; Fink, Daniel (1)
CS (1) Department of Obstetrics and Gynecology, University of Zurich,
CH-8091, Zurich: daniel.fink@fhk.usz.ch Switzerland
SO International Journal of Cancer, (15 August, 2001) Vol. 93, No. 4, pp.
571-576. print.
ISSN: 0020-7136.

DT Article
LA English
SL English

L2 ANSWER 9 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2001:417518 BIOSIS
DN PREV200100417518
TI Optimal adjuvant cytotoxic therapy for breast cancer.
AU Lohrisch, C.; Di Leo, A.; Piccart, M. J. (1)
CS (1) Jules Bordet Institute, 1 Rue Heger-Bordet, B-1000, Brussels:

mpiccart@ulb.ac.be Belgium
SO Breast, (August, 2001) Vol. 10, No. Supplement 3, pp. 106-113. print.
ISSN: 0960-9776.
DT General Review
LA English
SL English

L2 ANSWER 10 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2001:417515 BIOSIS
DN PREV200100417515
TI The use of anthracyclines and **taxanes** for adjuvant therapy of breast cancer.
AU Davidson, N. E. (1); Wolff, A. C.
CS (1) Johns Hopkins Oncology Center, 1650 Orleans Street, Room 409, Baltimore, MD, 21231-1000 USA
SO Breast, (August, 2001) Vol. 10, No. Supplement 3, pp. 90-95. print.
ISSN: 0960-9776.
DT General Review
LA English
SL English

L2 ANSWER 11 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2001:417196 BIOSIS
DN PREV200100417196
TI Selective tumor sensitization to **taxanes** with the mab-drug conjugate CBR96-**doxorubicin**.
AU Wahl, Alan F. (1); Donaldson, Karen L.; Mixan, Bruce J.; Trail, Pamela A.;
Siegall, Clay B.
CS (1) Seattle Genetics, Inc., 22215 26th Ave. SE, Bothell, WA, 98021: awahl@seagen.com USA
SO International Journal of Cancer, (15 August, 2001) Vol. 93, No. 4, pp. 590-600. print.
ISSN: 0020-7136.
DT Article
LA English
SL English

L2 ANSWER 12 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2001:306194 BIOSIS
DN PREV200100306194
TI Use of paclitaxel in patients with pre-existing cardiomyopathy: A review of our experience.
AU Gollerkeri, Ashwin; Harrold, Laurie; Rose, Michal; Jain, Diwaker; Burtness, Barbara Ann (1)
CS (1) Yale University School of Medicine, 333 Cedar Street, New Haven, CT, 06520: barbara.burtness@yale.edu USA
SO International Journal of Cancer, (1 July, 2001) Vol. 93, No. 1, pp. 139-141. print.
ISSN: 0020-7136.
DT Article
LA English
SL English

L2 ANSWER 13 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2001:294479 BIOSIS
DN PREV200100294479
TI Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.
AU Burstein, Harold J.; Kuter, Irene; Campos, Susana M.; Gelman, Rebecca S.;

Tribou, Laura; Parker, Leroy M.; Manola, Judith; Younger, Jerry; Matulonis, Ursula; Bunnell, Craig A.; Partridge, Ann H.; Richardson, Paul G.; Clarke, Kathryn; Shulman, Lawrence N.; Winer, Eric P. (1)
 CS (1) Dana-Farber Cancer Institute, 44 Binney St, Boston, MA, 02115: ewiner@partners.org USA
 SO Journal of Clinical Oncology, (May 15, 2001) Vol. 19, No. 10, pp. 2722-2730. print.
 ISSN: 0732-183X.
 DT Article
 LA English
 SL English

L2 ANSWER 14 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 2001:285475 BIOSIS
 DN PREV200100285475
 TI Neoadjuvant chemotherapy paxlitaxel+**doxorubicin** in the treatment of locally advanced breast cancer: Clinical, mammographic and pathological response.
 AU Semiglazov, V. F. (1); Bojok, A. A. (1); Arzumanov, A. A. (1); Klimashevsky, V. F. (1); Pozharissky, K. M. (1)
 CS (1) N.N. Petrov Research Institute of Oncology, Saint Petersburg Russia
 SO Breast, (February, 2001) Vol. 10, No. Supplement 1, pp. S33-S34. print.
 Meeting Info.: 7th International Conference on Adjuvant Therapy of Primary Breast Cancer Saint Gallen, Switzerland February 21-24, 2001
 ISSN: 0960-9776.
 DT Conference
 LA English
 SL English

L2 ANSWER 15 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 2001:283156 BIOSIS
 DN PREV200100283156
 TI Treatment of metastatic urothelial cancer in the post-MVAC era.
 AU Cohen, Ezra E. W.; Stadler, Walter M. (1)
 CS (1) 5841 South Maryland Avenue, Chicago, IL, 60637 USA
 SO World Journal of Urology, (April, 2001) Vol. 19, No. 2, pp. 126-132. print.
 ISSN: 0724-4983.
 DT Article
 LA English
 SL English

L2 ANSWER 16 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 2001:281724 BIOSIS
 DN PREV200100281724
 TI Induction chemotherapy for 465 operable breast cancers: The role of SBR grading and influence of complete pathological response on survival.
 AU Chollet, P. (1); Cure, H. (1); Penault-Llorca, F. (1); Le Bouedec, G. (1); Dauplat, J. (1)
 CS (1) Centre J. Perrin/Inserm U484, Clermont-Ferrand France
 SO Breast, (February, 2001) Vol. 10, No. Supplement 1, pp. S36-S37. print.
 Meeting Info.: 7th International Conference on Adjuvant Therapy of Primary Breast Cancer Saint Gallen, Switzerland February 21-24, 2001
 ISSN: 0960-9776.
 DT Conference
 LA English

SL English

L2 ANSWER 17 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2001:281653 BIOSIS
DN PREV200100281653
TI The use of anthracyclines and **taxanes** for adjuvant therapy of breast cancer.
AU Davidson, N. E. (1)
CS (1) Baltimore, MD USA
SO Breast, (February, 2001) Vol. 10, No. Supplement 1, pp. S9. print.
Meeting Info.: 7th International Conference on Adjuvant Therapy of Primary Breast Cancer Saint Gallen, Switzerland February 21-24, 2001
ISSN: 0960-9776.
DT Conference
LA English
SL English

L2 ANSWER 18 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2001:237244 BIOSIS
DN PREV200100237244
TI Lack of correlation between p53 expression, Bcl-2 expression, apoptosis and ex vivo chemosensitivity in advanced human breast cancer.
AU Rein, Daniel T. (1); Schoendorf, Thomas; Breidenbach, Martina; Janat, Margit M.; Weikelt, Astrid; Goehring, Uwe-Jochen; Becker, Martina; Mallmann, Peter; Kurbacher, Christian M.
CS (1) Department of Gynecology and Obstetrics, University of Cologne, Kerpener Strasse 34, D-50931, Cologne Germany
SO Anticancer Research, (November December, 2000) Vol. 20, No. 6D, pp. 5069-5072. print.
ISSN: 0250-7005.
DT Article
LA English
SL English

L2 ANSWER 19 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2000:539025 BIOSIS
DN PREV200000539025
TI Chemotherapy of metastatic breast cancer.
AU Brun, Bernard (1); Pouillart, Pierre
CS (1) Hopital Pitie-Salpetriere, 47-83, Boulevard de l'Hopital, 75013, Paris
France
SO Bulletin du Cancer (Montrouge), (September, 2000) Vol. 87, No. 9, pp. 643-653. print.
ISSN: 0007-4551.
DT Article
LA French
SL English; French

L2 ANSWER 20 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2000:458422 BIOSIS
DN PREV200000458422
TI Cisplatin plus vinorelbine as a salvage regimen in refractory breast cancer.
AU Gunel, Nazan (1); Akcali, Zafer; Yamac, Deniz; Onuk, Erhan; Yilmaz, Erdal;
Bayram, Orhan; Tekin, Ercument; Coskun, Ugur
CS (1) Planlamacilar Sitesi, 169. Sokak, No:6, Beysukent, Ankara, 06530 Turkey

SO Tumori, (July August, 2000) Vol. 86, No. 4, pp. 283-285. print.
ISSN: 0300-8916.

DT Article
LA English
SL English

L2 ANSWER 21 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2000:432916 BIOSIS
DN PREV200000432916
TI The role of chemotherapy in prostate cancer. Minireview.
AU Odrazka, K. (1); Vanasek, J.; Vaculikova, M. (1); Stejskal, J.; Filip, S. (1)
CS (1) Department of Oncology and Radiotherapy, Charles University Hospital, 500 05, Hradec Kralove Czech Republic
SO Neoplasma (Bratislava), (2000) Vol. 47, No. 4, pp. 197-203. print.
ISSN: 0028-2685.
DT General Review
LA English
SL English

L2 ANSWER 22 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2000:414155 BIOSIS
DN PREV200000414155
TI Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer.
AU Bellmunt, J. (1); Guillem, V.; Paz-Ares, L.; Gonzalez-Larriba, J. L.; Carles, J.; Albanell, J.; Tabernero, J. M.; Cortes-Funes, H.; Baselga, J.
CS (1) Hospital General Universitari Vall d'Hebron, P. Vall d'Hebron 119-129, 08035, Barcelona Spain
SO British Journal of Cancer, (August, 2000) Vol. 83, No. 4, pp. S17-S25. print.
ISSN: 0007-0920.
DT General Review
LA English
SL English

L2 ANSWER 23 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2000:414152 BIOSIS
DN PREV200000414152
TI Advanced bladder and urothelial cancers.
AU Raghavan, D. (1)
CS (1) Norris Comprehensive Cancer Center, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA, 90033 USA
SO British Journal of Cancer, (August, 2000) Vol. 83, No. 4, pp. S1-S6. print.
ISSN: 0007-0920.
DT General Review
LA English
SL English

L2 ANSWER 24 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2000:355732 BIOSIS
DN PREV200000355732
TI Experience with Caelyx(R) in the treatment of metastatic breast cancer.
AU Moebus, V. (1)
CS (1) Abteilung Gynaekologie, Universitaets-Frauen- und Poliklinik, Prittwitzstrasse 43, D-89075, Ulm Germany
SO Onkologie, (April, 2000) Vol. 23, No. Suppl. 2, pp. 20-25. print.

ISSN: 0378-584X.

DT Article
LA German
SL English; German

L2 ANSWER 25 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2000:355731 BIOSIS
DN PREV200000355731
TI Anthracyclines and Herceptin(R): New treatment option for patients with metastatic breast cancer.
AU Untch, M. (1); Crohns, C.; Kahlert, S.; Hepp, H.
CS (1) Klinik und Poliklinik fuer Frauenheilkunde und Geburtshilfe Klinikum Grosshadern, Ludwig-Maximilians-Universitaet, Marchioninistrasse 15, D-81377, Muenchen Germany
SO Onkologie, (April, 2000) Vol. 23, No. Suppl. 2, pp. 15-19. print.
ISSN: 0378-584X.

DT Article
LA German
SL English; German

L2 ANSWER 26 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2000:355730 BIOSIS
DN PREV200000355730
TI The role of anthracyclines in the treatment of metastatic breast cancer.
AU Kuhn, W. (1)
CS (1) Frauenklinik und Poliklinik, Klinikum rechts der Isar, Technische Universitaet Muenchen, Ismaninger Strasse 22, D-81675, Muenchen Germany
SO Onkologie, (April, 2000) Vol. 23, No. Suppl. 2, pp. 12-14. print.
ISSN: 0378-584X.

DT Article
LA German
SL English; German

L2 ANSWER 27 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2000:320408 BIOSIS
DN PREV200000320408
TI Introducing **taxanes** in the adjuvant treatment of breast cancer: Expectations and reality.
AU Colleoni, M. (1); Orlando, L.; Nole', F.; Goldhirsch, A.
CS (1) International Breast Cancer Study Group, Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan Italy
SO Breast, (June, 2000) Vol. 9, No. 3, pp. 134-138. print.
ISSN: 0960-9776.

DT General Review
LA English
SL English

L2 ANSWER 28 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2000:261868 BIOSIS
DN PREV200000261868
TI Onycholysis as a complication of systemic chemotherapy: Report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature.
AU Hussain, Sabir; Anderson, Dina N.; Salvatti, Mary Ellen; Adamson, Barbara;
McManus, Margaret; Braverman, Albert S. (1)
CS (1) Health Science Center at Brooklyn, State University of New York, 450 Clarkson Avenue, Brooklyn, NY, 11203-2098 USA
SO Cancer, (May 15, 2000) Vol. 88, No. 10, pp. 2367-2371. print..

ISSN: 0008-543X.
DT Article; General Review
LA English
SL English

L2 ANSWER 29 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2000:222035 BIOSIS
DN PREV200000222035
TI A unified definition of clinical anthracycline resistance breast cancer.
AU Pivot, X. (1); Asmar, L.; Buzdar, A. U.; Valero, V.; Hortobagyi, G.
CS (1) Centre Antoine Lacassagne, 33 avenue de Vallombrose, 06189, Nice
cedex, 2 France
SO British Journal of Cancer, (Feb., 2000) Vol. 82, No. 3, pp. 529-534.
ISSN: 0007-0920.
DT Article
LA English
SL English

L2 ANSWER 30 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2000:200012 BIOSIS
DN PREV200000200012
TI Preclinical evaluation of the cardiotoxicity of taxane-anthracycline
combinations using the model of isolated perfused rat heart.
AU Platel, Denis; Pouna, Paul; Bonoron-Adele, Simone; Robert, Jacques (1)
CS (1) 180 Rue de Saint-Genes, Institut Bergonie, 33076, Bordeaux-Cedex
France
SO Toxicology and Applied Pharmacology, (March 1, 2000) Vol. 163, No. 2, pp.
135-140.
ISSN: 0041-008X.
DT Article
LA English
SL English

=> d 12 31-64

L2 ANSWER 31 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2000:197884 BIOSIS
DN PREV200000197884
TI The effectiveness of present-day chemotherapy in patients with metastatic
breast cancer resistant to anthracyclin antibiotics.
AU Moiseyenko, V. M. (1); Orlova, R. V. (1)
CS (1) N.N.Petrov Research Institute of Oncology, Ministry of Health of the
RF, St. Petersburg Russia
SO Voprosy Onkologii (St. Petersburg), (1999) Vol. 45, No. 4, pp. 445-448.
ISSN: 0507-3758.
DT Article
LA Russian
SL English

L2 ANSWER 32 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2000:158568 BIOSIS
DN PREV200000158568
TI Treatment of liver metastases of breast cancer by chemotherapy without
taxanes.
AU Vosny, E. K. (1); Dobrovolskaya, N. Yu. (1); Goncharova, I. M. (1)
CS (1) Russian Center for Roentgeno-Radiology Research, the Ministry of
Health of the RF, Moscow Russia
SO Voprosy Onkologii (St. Petersburg)., (1999) Vol. 45, No. 2, pp. 189-193.
ISSN: 0507-3758.

DT Article
LA Russian
SL English

L2 ANSWER 33 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2000:127104 BIOSIS
DN PREV2000000127104

TI Resistance to **taxanes** is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A.

AU Ciardiello, Fortunato (1); Caputo, Rosa; Pomatico, Grazia; De Laurentiis, Michelino; De Placido, Sabino; Bianco, A. Raffaele; Tortora, Giampaolo
CS (1) Cattedra di Oncologia Medica, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Universita degli Studi di Napoli Federico II, Via S. Pansini, 5, I-80131, Naples Italy
SO International Journal of Cancer, (Marrch 1, 2000) Vol. 85, No. 5, pp. 710-715.
ISSN: 0020-7136.

DT Article
LA English
SL English

L2 ANSWER 34 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2000:78669 BIOSIS
DN PREV200000078669

TI **Taxanes**: An overview of the pharmacokinetics and pharmacodynamics.

AU Vaishampayan, Ulka; Parchment, Ralph E.; Jasti, Bhaskara R.; Hussain, Maha
(1)
CS (1) Harper Hospital, 3990 John R Road, 5 Hudson, Detroit, MI USA
SO Urology, (Dec., 1999) Vol. 54, No. 6A SUPPL., pp. 22-29.
ISSN: 0090-4295.

DT General Review
LA English
SL English

L2 ANSWER 35 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1999:538124 BIOSIS
DN PREV199900538124

TI In vitro sequence dependence for the multitargeted antifolate (MTA, LY231514) combined with other anticancer agents.

AU Schultz, R. M. (1); Dempsey, J. A. (1); Kraus, L. A.; Schmid, S. M.; Calvete, J. A.; Laws, A. L.
CS (1) Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, IN, 46285 USA
SO European Journal of Cancer, (Sept., 1999) Vol. 35, No. SUPPL. 4, pp. S194.

Meeting Info.: ECCO 10: The European Cancer Conference Vienna, Austria September 12-16, 1999 Federation of European Cancer Societies
. ISSN: 0959-8049.

DT Conference
LA English

L2 ANSWER 36 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1999:492322 BIOSIS
DN PREV199900492322

TI Recent advances in adjuvant therapy of breast cancer.
AU Buzdar, Aman U. (1); Hortobagyi, Gabriel N.

CS (1) University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd,
Houston, TX, 77030 USA
SO Seminars in Oncology, (Aug., 1999) Vol. 26, No. 4 SUPPL. 12, pp. 21-27.
ISSN: 0093-7754.
DT Article; General Review
LA English

L2 ANSWER 37 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1999:453170 BIOSIS
DN PREV199900453170
TI DNA damage increases sensitivity to Vinca alkaloids and decreases
sensitivity to **taxanes** through p53-dependent repression of
microtubule-associated protein 41.
AU Zhang, Christine C.; Yang, Jin-Ming; Bash-Babula, Judy; White, Eileen;
Murphy, Maureen; Levine, Arnold J.; Hait, William N. (1)
CS (1) Cancer Institute of New Jersey, 195 Little Albany Street, New
Brunswick, NJ, 08901 USA
SO Cancer Research, (Aug. 1, 1999) Vol. 59, No. 15, pp. 3663-3670.
ISSN: 0008-5472.
DT Article
LA English
SL English

L2 ANSWER 38 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1999:425312 BIOSIS
DN PREV199900425312
TI **Doxorubicin**/taxane combinations: Cardiac toxicity and
pharmacokinetics.
AU Sparano, Joseph A. (1)
CS (1) Albert Einstein Comprehensive Cancer Center, Weiler Division-2 South,
Montefiore Medical Center, 1825 Eastchester Rd, Room 52, Bronx, NY, 10461
USA
SO Seminars in Oncology, (June, 1999) Vol. 26, No. 3 SUPPL. 9, pp. 14-19.
ISSN: 0093-7754.
DT Article
LA English

L2 ANSWER 39 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1999:392820 BIOSIS
DN PREV199900392820
TI Metastatic breast cancer: The role of chemotherapy.
AU Sledge, George W., Jr. (1); Miller, Kathy D.
CS (1) 535 Barnhill Dr, Indiana Cancer Pavilion RT-473, Indianapolis, IN,
46202 USA
SO Seminars in Oncology, (Feb., 1999) Vol. 26, No. 1 SUPPL. 2, pp. 6-10.
Meeting Info.: The Fox Chase Cancer Center and Free University Hospital
Investigators Workshop and Consensus Conference on Paclitaxel St. Thomas,
Virgin Islands, USA March 25-29, 1998 Fox Chase Cancer Center
. ISSN: 0093-7754.
DT Conference
LA English

L2 ANSWER 40 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1999:242887 BIOSIS
DN PREV199900242887
TI Inhibitory effects of combinations of HER-2/neu antibody and
chemotherapeutic agents used for treatment of human breast cancers.
AU Pegram, Mark; Hsu, Sheree; Lewis, Gail; Pietras, Richard; Beryt,
Malgorzata; Sliwkowski, Mark; Coombs, Daniel; Baly, Deborah; Kabbinar,
Fairooz; Slamon, Dennis (1)

CS (1) Department of Medicine, Division of Hematology-Oncology, UCLA School
of Medicine, 11-934 Factor Building, Los Angeles, CA, 90095 USA
SO Oncogene, (April 1, 1999) Vol. 18, No. 13, pp. 2241-2251.
ISSN: 0950-9232.
DT Article
LA English
SL English

L2 ANSWER 41 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1999:230549 BIOSIS
DN PREV199900230549
TI 5-Year results of dose-intensive sequential adjuvant chemotherapy for
women with high-risk node-positive breast cancer: A phase II study.
AU Hudis, C. (1); Fornier, M.; Riccio, L.; Lebwahl, D.; Crown, J.; Gilewski,
T.; Surbone, A.; Currie, V.; Seidman, A.; Reichman, B.; Moynahan, M.;
Raptis, G.; Sklarin, N.; Theodoulou, M.; Weiselberg, L.; Salvaggio, R.;
Panageas, K. S.; Yao, T. J.; Norton, L.
CS (1) Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY,
10021 USA
SO Journal of Clinical Oncology, (April, 1999) Vol. 17, No. 4, pp.
1118-1126.
ISSN: 0732-183X.
DT Article
LA English
SL English

L2 ANSWER 42 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1999:207237 BIOSIS
DN PREV199900207237
TI The systemic treatment of AIDS-related Kaposi's sarcoma.
AU Schwartzmann, G. (1); Stefani, S.; Villarroel, R. U.
CS (1) Med. Oncol. Unit, Hosp. Clin. Porto Alegre, Rua Ramino Barcelos
2350/3
leste, Porto Alegre, RS Brazil
SO Cancer Treatment Reviews, (Dec., 1998) Vol. 24, No. 6, pp. 415-424.
ISSN: 0305-7372.
DT General Review
LA English

L2 ANSWER 43 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1999:182064 BIOSIS
DN PREV199900182064
TI DNA damaging agents increase wild type p53, suppress microtubule
associated protein 4 (MAP4), sensitize cells to vinca alkaloids and
render
cells resistant to **taxanes**.
AU Zhang, C.; Bash, J. E.; Hait, W. N.
CS Cancer Inst. New Jersey, UMDNJ/RWJMS, New Brunswick, NJ 08901 USA
SO Proceedings of the American Association for Cancer Research Annual
Meeting, (March, 1999) Vol. 40, pp. 95-96.
Meeting Info.: 90th Annual Meeting of the American Association for Cancer
Research Philadelphia, Pennsylvania, USA April 10-14, 1999 American
Association for Cancer Research
. ISSN: 0197-016X.
DT Conference
LA English

L2 ANSWER 44 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1999:170403 BIOSIS
DN PREV199900170403

TI A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts.
 AU Polizzi, Donatella; Pratesi, Graziella; Tortoreto, Monica; Supino, Rosanna; Riva, Antonella; Bombardelli, Ezio; Zunino, Franco (1)
 CS (1) Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan Italy
 SO Cancer Research, (March 1, 1999) Vol. 59, No. 5, pp. 1036-1040.
 ISSN: 0008-5472.
 DT Article
 LA English

L2 ANSWER 45 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1999:101807 BIOSIS
 DN PREV199900101807
 TI **Taxanes** in combination with **doxorubicin** in the treatment of metastatic breast cancer.
 AU Dieras, Veronique (1)
 CS (1) Institut Curie, 26 rue Ulm, 75005 Paris Cedex 5 France
 SO Seminars in Oncology, (Oct., 1998) Vol. 25, No. 5 SUPPL. 12, pp. 18-22.
 ISSN: 0093-7754.
 DT Article
 LA English

L2 ANSWER 46 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1998:513450 BIOSIS
 DN PREV199800513450
 TI Weekly continuous infusion of 5-fluorouracil with oral leucovorin in metastatic breast cancer patients with primary resistance to **doxorubicin**.
 AU Nieto, Yago (1); Martin, Miguel; Alonso, Jose Luis; Casado, Antonio; Ayala, Francisco; Lopez-Martin, Jose Antonio; Rodriguez-Lescure, Alvaro; Diaz-Rubio, Eduardo
 CS (1) Univ. Colorado Health Sci. Cent., Box B190, 4200 East Ninth Ave., Denver, CO 80262 USA
 SO Breast Cancer Research and Treatment, (July, 1998) Vol. 50, No. 2, pp. 167-174.
 ISSN: 0167-6806.
 DT Article
 LA English

L2 ANSWER 47 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1998:238079 BIOSIS
 DN PREV199800238079
 TI Structure-activity relationship studies of new **taxanes** as reversal agents for multi-drug resistance in cancer cells.
 AU Ojima, Iwao (1); Bounaud, Pierre-Yves (1); Takeuchi, Criag (1); Liang, Catherine (1); Eppich, Simone M.-G. (1); Pera, Paula; Bernacki, Ralph J.
 CS (1) Dep. Chem., State Univ. New York at Stony Brook, Stony Brook, NY 11794-3400 USA
 SO Abstracts of Papers American Chemical Society, (1998) Vol. 215, No. 1-2, pp. MEDI 12.
 Meeting Info.: 215th American Chemical Society National Meeting Dallas, Texas, USA March 29-April 2, 1998 American Chemical Society
 . ISSN: 0065-7727.
 DT Conference
 LA English

L2 ANSWER 48 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1998:230993 BIOSIS
 DN PREV199800230993
 TI New developments in cancer treatment with the novel thymidylate synthase

inhibitor raltitrexed ('Tomudex.
AU Blackledge, G. (1)
CS (1) Clin. Res. Group, Zeneca Pharm., Mereside, Alderley Park,
Macclesfield, Cheshire SK10 4TG UK
SO British Journal of Cancer, (1998) Vol. 77, No. SUPPL. 2, pp. 29-37.
ISSN: 0007-0920.
DT Article
LA English

L2 ANSWER 49 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1998:126466 BIOSIS
DN PREV199800126466
TI New **taxanes** as highly efficient reversal agents for multi-drug
resistance in cancer cells.
AU Ojima, Iwao (1); Bounaud, Pierre-Yves; Takeuchi, Craig; Pera, Paula;
Bernacki, Ralph J.
CS (1) Dep. Chem., State Univ. New York Stony Brook, Stony Brook, NY
11794-3400 USA
SO Bioorganic & Medicinal Chemistry Letters, (Jan. 20, 1998) Vol. 8, No. 2,
pp. 189-194.
ISSN: 0960-894X.
DT Article
LA English

L2 ANSWER 50 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1998:80650 BIOSIS
DN PREV199800080650
TI Effects of tubulin-inhibiting agents in human lung and breast cancer cell
lines with different multidrug resistance phenotypes.
AU Van Ark-Otte, Jannette; Samelis, Giorgos; Rubio, Gonzalo; Lopez Saez,
Jose-Bosco; Pinedo, Herbert M.; Giaccone, Giuseppe (1)
CS (1) Dep. Oncol., University Hosp. Vrije Universiteit, De Boelelaan 1117,
HV 1081 Amsterdam Netherlands
SO Oncology Reports, (Jan.-Feb., 1998) Vol. 5, No. 1, pp. 249-255.
ISSN: 1021-335X.
DT Article
LA English

L2 ANSWER 51 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1997:539671 BIOSIS
DN PREV199799838874
TI Sequence-dependent synergy of **taxanes** and topoisomerase I
inhibitors in human breast cancer cell lines.
AU Madden, Timothy; Newman, Robert A.; Tran, Hai T.
CS Univ. Texas MD Anderson Cancer Cent., Houston, TX USA
SO Pharmacotherapy, (1997) Vol. 17, No. 5, pp. 1089.
Meeting Info.: Annual Meeting of the American College of Clinical
Pharmacy
Phoenix, Arizona, USA November 9-12, 1997
ISSN: 0277-0008.
DT Conference; Abstract
LA English

L2 ANSWER 52 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1997:491814 BIOSIS
DN PREV199799791017
TI Drug interactions with the **taxanes**.
AU Baker, Sharyn D.
CS Inst. Drug Development, Cancer Therapy Res. Cent., 7703 Floyd Curl Dr.,
McDermott Build., 3rd Floor, San Antonio, TX 78284-6220 USA

SO Pharmacotherapy, (1997) Vol. 17, No. 5 PART 2, pp. 126S-132S.
ISSN: 0277-0008.
DT Journal; Article
LA English

L2 ANSWER 53 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1997:491813 BIOSIS
DN PREV199799791016
TI Clinical overview of the **taxanes**.
AU Goldspiel, Barry R.
CS Natl. Institutes Health, 10 Center Dr.-MSC 1196, Build. 10, Room 1N-257,
Bethesda, MD 20892-1196 USA
SO Pharmacotherapy, (1997) Vol. 17, No. 5 PART 2, pp. 110S-125S.
ISSN: 0277-0008.
DT General Review
LA English

L2 ANSWER 54 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1997:261867 BIOSIS
DN PREV199799568470
TI Human pharmacokinetic characterization and in vitro study of the
interaction between **doxorubicin** and paclitaxel in patients with
breast cancer.
AU Gianni, Luca (1); Vigano, Lucia; Locatelli, Alberta; Capri, Giuseppe;
Giani, Antonio; Tarenzi, Emiliana; Bonadonna, Gianni
CS (1) Lab. Clin. Pharmacol., Div. Medical Oncol. A, Istituto Nazionale
Tumori, Via Venezian 1, 20133 Milano Italy
SO Journal of Clinical Oncology, (1997) Vol. 15, No. 5, pp. 1906-1915.
ISSN: 0732-183X.
DT Article
LA English

L2 ANSWER 55 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1997:197882 BIOSIS
DN PREV199799497085
TI Synthesis and evaluation of new taxane-based reversal agents.
AU Ojima, Iwao (1); Bounaud, Pierre-Yves (1); Pera, Paula; Veith, Jean M.;
Bernacki, Ralph J.
CS (1) Dep. Chem., State Univ. New York Stony Brook, Stony Brook, NY
11794-3400 USA
SO Abstracts of Papers American Chemical Society, (1997) Vol. 213, No. 1-3,
pp. MEDI 209.
Meeting Info.: 213th National Meeting of the American Chemical Society
San Francisco, California, USA April 13-17, 1997
ISSN: 0065-7727.
DT Conference; Abstract
LA English

L2 ANSWER 56 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1997:197881 BIOSIS
DN PREV199799497084
TI New **taxanes** as highly efficient reversal agents for multi-drug
resistance in cancer cells.
AU Ojima, Iwao (1); Bounaud, Pierre-Yves (1); Takeuchi, Craig (1); Pera,
Paula; Veith, Jean M.; Bernacki, Ralph J.
CS (1) Dep. Chem., State Univ. New York Stony Brook, Stony Brook, NY
11794-3400 USA
SO Abstracts of Papers American Chemical Society, (1997) Vol. 213, No. 1-3,
pp. MEDI 208.

Meeting Info.: 213th National Meeting of the American Chemical Society
 San Francisco, California, USA April 13-17, 1997
 ISSN: 0065-7727.
 DT Conference; Abstract
 LA English

L2 ANSWER 57 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1997:31637 BIOSIS
 DN PREV199799338040
 TI Chemotherapy and chemo-radiotherapy of advanced pancreatic carcinoma.
 AU Mergenthaler, H.-G. (1); Lueftner, D.; Possinger, K.
 CS (1) Med. Klinik Poliklinik II, Universitaetsklin. Charite,
 Schumannstrasse
 20-21, D-10117 Berlin Germany
 SO Onkologie, (1996) Vol. 19, No. 4, pp. 308-312.
 ISSN: 0378-584X.
 DT General Review
 LA English
 SL English; German

L2 ANSWER 58 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1997:856 BIOSIS
 DN PREV199799300059
 TI Management of metastatic bladder cancer.
 AU Loehrer, Patrick J., Sr. (1); De Mulder, Pieter H. M.
 CS (1) Indiana Univ. Med. Cent., Indianapolis, IN USA
 SO Raghavan, D.; Leibel, S. A.; Scher, H. I.; Lange, P.. (1997) pp. 299-305.
 Principles and practice of genitourinary oncology.
 Publisher: Lippincott-Raven Publishers 227 East Washington Square,
 Philadelphia, Pennsylvania 19106, USA.
 ISBN: 0-397-51458-1.
 DT Book
 LA English

L2 ANSWER 59 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1996:465584 BIOSIS
 DN PREV199699187940
 TI New promising anticancer agents in development: What comes next.
 AU Verweij, Jaap
 CS Dep. Med. Oncol., Div. Experimental Chemotherapy Pharmacol., Rotterdam
 Cancer Inst., Univ. Hosp., Groene Hilledijk 301, 3075 EA Rotterdam
 Netherlands
 SO Cancer Chemotherapy and Pharmacology, (1996) Vol. 38, No. SUPPL., pp.
 S3-S10.
 ISSN: 0344-5704.
 DT Article
 LA English

L2 ANSWER 60 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1996:335607 BIOSIS
 DN PREV199699057963
 TI Chemotherapy for invasive bladder cancer.
 AU Malkowicz, S. Bruce (1); Vaughn, David J.
 CS (1) Div. Urology, 1 Rhoads, 3400 Spuce Street, Univ. Pennsylvania Med.
 Cent., Philadelphia, PA 19104 USA
 SO Urology, (1996) Vol. 47, No. 4, pp. 602-614.
 ISSN: 0090-4295.
 DT General Review
 LA English

L2 ANSWER 61 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1996:271398 BIOSIS
 DN PREV199698827527
 TI Recurrent breast cancer treated successfully with mitomycin-C and
 vinblastine after failure of both **doxorubicin**-containing regimen
 and paclitaxel: A case report.
 AU Sekine, Ikuo; Sasaki, Yasutsuna (1); Fujii, Hirobumi; Ohtsu, Tomoko;
 Wakita, Hisashi; Igarashi, Tadahiko; Itoh, Kuniaki; Abe, Kaoru
 CS (1) Div. Oncol./Hematol., Natl. Cancer Cent. Hosp. E., 6-5-1,
 Kashiwanoha,
 Kashiwa, Chiba 277 Japan
 SO Tohoku Journal of Experimental Medicine, (1996) Vol. 178, No. 3, pp.
 331-337.
 ISSN: 0040-8727.
 DT Article
 LA English

L2 ANSWER 62 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1996:256675 BIOSIS
 DN PREV199698812804
 TI Combination regimens of fludarabine and ara-C followed by **taxanes**
 (docetaxel and paclitaxel) against human leukemia T-cell lines, CEM/0 and
 CEM/ara-C/7A.
 AU Kwok, R.; Nandy, P.; Solorzano, M.; Avramis, V. I.
 CS Div. Hema./Oncol., USC Sch. Med., Childrens Hosp. LA, Los Angeles, CA
 90027 USA
 SO Proceedings of the American Association for Cancer Research Annual
 Meeting, (1996) Vol. 37, No. 0, pp. 377.
 Meeting Info.: 87th Annual Meeting of the American Association for Cancer
 Research Washington, D.C., USA April 20-24, 1996
 ISSN: 0197-016X.
 DT Conference
 LA English

L2 ANSWER 63 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1996:245235 BIOSIS
 DN PREV199698801364
 TI The role of **taxanes** in the treatment of breast cancer.
 AU Capri, G.; Tarenzi, E.; Fulfaro, F.; Gianni, L. (1)
 CS (1) Inst. Naz. Tumori, Via Venezian 1, 20133 Milano Italy
 SO Seminars in Oncology, (1996) Vol. 23, No. 1 SUPPL. 2, pp. 68-75.
 ISSN: 0093-7754.
 DT General Review
 LA English

L2 ANSWER 64 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1995:209103 BIOSIS
 DN PREV199598223403
 TI In vitro activity of taxol and taxotere in comparison with
doxorubicin and cisplatin on primary cell cultures of human breast
 cancers.
 AU Zoli, Wainer; Flamigni, Alberto; Frassineti, Giovanni Luca; Bajorko,
 Paola; De Paola, Franca; Milandri, Carlo; Amadori, Dino (1);
 Gasperi-Campani, Anna
 CS (1) Dep. Med. Oncol., G.B. Morgagni-L. Pierantoni Hosp., U.S.L. 38, Viale
 Forlanini, 47100 Forli Italy
 SO Breast Cancer Research and Treatment, (1995) Vol. 34, No. 1, pp. 63-69.
 ISSN: 0167-6806.
 DT Article

LA English

=> d 12 abs ibib 54,45,38,64,61,17,14,10,5

L2 ANSWER 54 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AB Purpose: We performed a pharmacologic investigation paclitaxel (PTX) infused over 3 hours and bolus **doxorubicin** (DOX) to assess the role of sequence, interval between drugs, and duration of **doxorubicin** infusion on paclitaxel and anthracycline plasma disposition. We also explored possible mechanisms of pharmacokinetic interference involving the physiologic role of the multidrug resistance phenotype in anthracycline and taxane biliary excretion. Patients and Methods: Pharmacokinetics was performed in 80 cycles and 36 women with previously untreated metastatic breast cancer. PTX, DOX, and their metabolites 6-alpha-hydroxyl-PTX (6-alpha-OH-PTX) and **doxorubicinol** (DOL) were measured by high-pressure liquid chromatography (HPLC). Human breast cancer MCF-7 wild-type (WT) and resistant (TH) cell lines were cultured in whole human plasma to study anthracycline retention after treatment with different combinations of PTX, Cremophor EL (CEL) (PEG35 castor oil; BASF, Parsippany, NJ), and

DOX. Results: Pharmacokinetic interference between PTX and DOX was responsible for nonlinearity of DOX plasma disposition and increased concentrations

of DOX and DOL. These effects were PTX dose-dependent, DOX concentration-dependent, and likely a result of interference at the level of liver elimination. In view of the physiologic role of P-glycoproteins (P-gp) in xenobiotic biliary excretion, retention of DOX was assessed in MCF-7 WT and MCF-7 TH cells. Intracellular was significantly higher in MCF-7 WT than MCF-7 TH (P < .05). However, concomitant exposure to DOX, PTX, and CEL caused similar DOX retention in both MCF-7 WT and TH cells. Conclusion: PTX, as clinically formulated in CEL, is responsible for a nonlinear disposition of DOX and DOL. Nonlinearity is PTX- and DOX-dependent, and possibly caused by competition for biliary excretion

of taxanes and anthracyclines mediated by P-gp. Nonlinearity indicates that even minor modifications of dose and infusion duration of DOX and PTX may lead to unpredictable pharmacodynamic consequences. The postulated role of P-gp suggests that CEL is clinically active, and advises caution in designing combinations of PTX with other drugs that

are substrate for P-gp.

ACCESSION NUMBER: 1997:261867 BIOSIS

DOCUMENT NUMBER: PREV199799568470

TITLE: Human pharmacokinetic characterization and in vitro study of the interaction between **doxorubicin** and paclitaxel in patients with breast cancer.

AUTHOR(S): Gianni, Luca (1); Vigano, Lucia; Locatelli, Alberta; Capri,

Giuseppe; Giani, Antonio; Tarenzi, Emiliana; Bonadonna, Gianni

CORPORATE SOURCE: (1) Lab. Clin. Pharmacol., Div. Medical Oncol. A, Istituto Nazionale Tumori, Via Venezian 1, 20133 Milano Italy

SOURCE: Journal of Clinical Oncology, (1997) Vol. 15, No. 5, pp. 1906-1915.

ISSN: 0732-183X.

DOCUMENT TYPE: Article

LANGUAGE: English

L2 ANSWER 45 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 1999:101807 BIOSIS
DOCUMENT NUMBER: PREV199900101807
TITLE: **Taxanes** in combination with **doxorubicin**
in the treatment of metastatic breast cancer.
AUTHOR(S): Dieras, Veronique (1)
CORPORATE SOURCE: (1) Institut Curie, 26 rue Ulm, 75005 Paris Cedex 5 France
SOURCE: Seminars in Oncology, (Oct., 1998) Vol. 25, No. 5 SUPPL.
12, pp. 18-22.
ISSN: 0093-7754.
DOCUMENT TYPE: Article
LANGUAGE: English

L2 ANSWER 38 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 1999:425312 BIOSIS
DOCUMENT NUMBER: PREV199900425312
TITLE: **Doxorubicin**/taxane combinations: Cardiac toxicity
and pharmacokinetics.
AUTHOR(S): Sparano, Joseph A. (1)
CORPORATE SOURCE: (1) Albert Einstein Comprehensive Cancer Center, Weiler
Division-2 South, Montefiore Medical Center, 1825
Eastchester Rd, Room 52, Bronx, NY, 10461 USA
SOURCE: Seminars in Oncology, (June, 1999) Vol. 26, No. 3 SUPPL.
9,
pp. 14-19.
ISSN: 0093-7754.
DOCUMENT TYPE: Article
LANGUAGE: English

L2 ANSWER 64 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AB The in vitro activities of taxol and taxotere in comparison with
cisplatin
and **doxorubicin** were assessed in 30 primary tumor cultures from
human breast cancers. Both **taxanes** were much more potent than
cisplatin and **doxorubicin**. Taxotere was 3.1, 296, and 9.6-fold
more cytotoxic than taxol, cisplatin, and **doxorubicin**
respectively. The cytotoxic activity observed in our experiments confirms
the potential clinical relevance of the two **taxanes** in the
management of breast cancer.
ACCESSION NUMBER: 1995:209103 BIOSIS
DOCUMENT NUMBER: PREV199598223403
TITLE: In vitro activity of taxol and taxotere in comparison with
doxorubicin and cisplatin on primary cell cultures
of human breast cancers.
AUTHOR(S): Zoli, Wainer; Flamigni, Alberto; Frassinetti, Giovanni
Luca;
Bajorko, Paola; De Paola, Franca; Milandri, Carlo;
Amadori,
Dino (1); Gasperi-Campani, Anna
CORPORATE SOURCE: (1) Dep. Med. Oncol., G.B. Morgagni-L. Pierantoni Hosp.,
U.S.L. 38, Viale Forlanini, 47100 Forli Italy
SOURCE: Breast Cancer Research and Treatment, (1995) Vol. 34, No.
1, pp. 63-69.
ISSN: 0167-6806.
DOCUMENT TYPE: Article
LANGUAGE: English

L2 ANSWER 61 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AB Cross-resistance is one of the chief obstacles in salvage therapy for
refractory breast cancer. Although paclitaxel is one of the most
promising

drugs, it shows a response rate of 30% at most for patients with breast cancer resistant to **doxorubicin**, and no effective treatments for tumors refractory to both agents have been reported. We describe a 38-year-old woman with recurrent breast cancer, who was treated successfully with mitomycin-C and vinblastine after **doxorubicin**-based chemotherapy and paclitaxel failed. The combinations of mitomycin-C

and microtubule inhibitors including vinca alkaloids and **taxanes** may have a potential application to refractory breast cancer.

ACCESSION NUMBER: 1996:271398 BIOSIS
DOCUMENT NUMBER: PREV199698827527
TITLE: Recurrent breast cancer treated successfully with mitomycin-C and vinblastine after failure of both **doxorubicin**-containing regimen and paclitaxel: A case report.
AUTHOR(S): Sekine, Ikuo; Sasaki, Yasutsuna (1); Fujii, Hirobumi; Ohtsu, Tomoko; Wakita, Hisashi; Igarashi, Tadahiko; Itoh, Kuniaki; Abe, Kaoru
CORPORATE SOURCE: (1) Div. Oncol./Hematol., Natl. Cancer Cent. Hosp. E., 6-5-1, Kashiwanoha, Kashiwa, Chiba 277 Japan
SOURCE: Tohoku Journal of Experimental Medicine, (1996) Vol. 178, No. 3, pp. 331-337.
ISSN: 0040-8727.
DOCUMENT TYPE: Article
LANGUAGE: English

L2 ANSWER 17 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2001:281653 BIOSIS
DOCUMENT NUMBER: PREV200100281653
TITLE: The use of anthracyclines and **taxanes** for adjuvant therapy of breast cancer.
AUTHOR(S): Davidson, N. E. (1)
CORPORATE SOURCE: (1) Baltimore, MD USA
SOURCE: Breast, (February, 2001) Vol. 10, No. Supplement 1, pp. S9.
print.
Meeting Info.: 7th International Conference on Adjuvant Therapy of Primary Breast Cancer Saint Gallen, Switzerland February 21-24, 2001
ISSN: 0960-9776.
DOCUMENT TYPE: Conference
LANGUAGE: English
SUMMARY LANGUAGE: English

L2 ANSWER 14 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2001:285475 BIOSIS
DOCUMENT NUMBER: PREV200100285475
TITLE: Neoadjuvant chemotherapy paxlitaxel+**doxorubicin** in the treatment of locally advanced breast cancer: Clinical, mammographic and pathological response.
AUTHOR(S): Semiglazov, V. F. (1); Bojok, A. A. (1); Arzumanov, A. A. (1); Klimashevsky, V. F. (1); Pozharissky, K. M. (1)
CORPORATE SOURCE: (1) N.N. Petrov Research Institute of Oncology, Saint Petersburg Russia
SOURCE: Breast, (February, 2001) Vol. 10, No. Supplement 1, pp. S33-S34. print.
Meeting Info.: 7th International Conference on Adjuvant Therapy of Primary Breast Cancer Saint Gallen, Switzerland February 21-24, 2001
ISSN: 0960-9776.

DOCUMENT TYPE: Conference
LANGUAGE: English
SUMMARY LANGUAGE: English

L2 ANSWER 10 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AB The anthracyclines (**doxorubicin** and epirubicin) and **taxanes** (paclitaxel and docetaxel) are among the most active agents for the treatment of advanced breast cancer. The efficacy and safety of anthracycline-taxane combinations have been established in this setting. As a consequence, their use in early-stage breast cancer is an area of active investigation. Two general strategies have been pursued - combinations of taxane and anthracycline and sequential use of anthracycline followed by taxane or the reverse. This review summarizes our current knowledge about the adjuvant use of **doxorubicin** and paclitaxel or docetaxel for breast cancer, focusing on randomized clinical trials of the US cooperative groups as examples of the development process.

ACCESSION NUMBER: 2001:417515 BIOSIS
DOCUMENT NUMBER: PREV200100417515
TITLE: The use of anthracyclines and **taxanes** for adjuvant therapy of breast cancer.
AUTHOR(S): Davidson, N. E. (1); Wolff, A. C.
CORPORATE SOURCE: (1) Johns Hopkins Oncology Center, 1650 Orleans Street, Room 409, Baltimore, MD, 21231-1000 USA
SOURCE: Breast, (August, 2001) Vol. 10, No. Supplement 3, pp. 90-95. print.
ISSN: 0960-9776.
DOCUMENT TYPE: General Review
LANGUAGE: English
SUMMARY LANGUAGE: English

L2 ANSWER 5 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2001:476688 BIOSIS
DOCUMENT NUMBER: PREV200100476688
TITLE: Pharmacokinetic profiles of **doxorubicin** in combination with **taxanes**.
AUTHOR(S): Holmes, Frankie Ann (1); Rowinsky, Eric Keith
CORPORATE SOURCE: (1) 909 Frostwood Dr, No. 221, Houston, TX, 77024-2305 USA
SOURCE: Seminars in Oncology, (August, 2001) Vol. 28, No. 4 Suppl 12, pp. 8-14. print.
ISSN: 0093-7754.
DOCUMENT TYPE: Article
LANGUAGE: English
SUMMARY LANGUAGE: English

=> d l2 abs ibib 45

L2 ANSWER 45 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 1999:101807 BIOSIS
DOCUMENT NUMBER: PREV199900101807
TITLE: **Taxanes** in combination with **doxorubicin** in the treatment of metastatic breast cancer.
AUTHOR(S): Dieras, Veronique (1)
CORPORATE SOURCE: (1) Institut Curie, 26 rue Ulm, 75005 Paris Cedex 5 France
SOURCE: Seminars in Oncology, (Oct., 1998) Vol. 25, No. 5 SUPPL. 12, pp. 18-22.
ISSN: 0093-7754.
DOCUMENT TYPE: Article

LANGUAGE: English

=> d 12 abs ibib 38

L2 ANSWER 38 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 1999:425312 BIOSIS
DOCUMENT NUMBER: PREV199900425312
TITLE: **Doxorubicin**/taxane combinations: Cardiac toxicity
and pharmacokinetics.
AUTHOR(S): Sparano, Joseph A. (1)
CORPORATE SOURCE: (1) Albert Einstein Comprehensive Cancer Center, Weiler
Division-2 South, Montefiore Medical Center, 1825
Eastchester Rd, Room 52, Bronx, NY, 10461 USA
SOURCE: Seminars in Oncology, (June, 1999) Vol. 26, No. 3 SUPPL.
9,
pp. 14-19.
ISSN: 0093-7754.
DOCUMENT TYPE: Article
LANGUAGE: English

=> d 12 abs ibib 17

L2 ANSWER 17 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 2001:281653 BIOSIS
DOCUMENT NUMBER: PREV200100281653
TITLE: The use of anthracyclines and **taxanes** for
adjuvant therapy of breast cancer.
AUTHOR(S): Davidson, N. E. (1)
CORPORATE SOURCE: (1) Baltimore, MD USA
SOURCE: Breast, (February, 2001) Vol. 10, No. Supplement 1, pp.
S9.
print.
Meeting Info.: 7th International Conference on Adjuvant
Therapy of Primary Breast Cancer Saint Gallen, Switzerland
February 21-24, 2001
ISSN: 0960-9776.
DOCUMENT TYPE: Conference
LANGUAGE: English
SUMMARY LANGUAGE: English

=> d 12 abs ibib 14

L2 ANSWER 14 OF 64 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 2001:285475 BIOSIS
DOCUMENT NUMBER: PREV200100285475
TITLE: Neoadjuvant chemotherapy paxlitaxel+**doxorubicin**
in the treatment of locally advanced breast cancer:
Clinical, mammographic and pathological response.
AUTHOR(S): Semiglazov, V. F. (1); Bojok, A. A. (1); Arzumanov, A. A.
(1); Klimashevsky, V. F. (1); Pozharissky, K. M. (1)
CORPORATE SOURCE: (1) N.N. Petrov Research Institute of Oncology, Saint
Petersburg Russia
SOURCE: Breast, (February, 2001) Vol. 10, No. Supplement 1, pp.
S33-S34. print.
Meeting Info.: 7th International Conference on Adjuvant
Therapy of Primary Breast Cancer Saint Gallen, Switzerland
February 21-24, 2001

,

SINCE FILE

ENTRY

SESSION

159.87

160.54

STN INTERNATIONAL LOGOFF AT 12:06:20 ON 30 JAN 2002